Click here to read this study in the Journal of Clinical Oncology ©2024 2 Minute Medicine, Inc. All rights reserved. No ...
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group for ...
![Maternal cell-free DNA sequencing superior to standard aneuploidy screening [CARE Study]](https://www.2minutemedicine.com/wp-content/uploads/2014/02/47-karyotype-350x250.jpg)
1. Pathogenic variants of BRCA1 or BRCA2 are associated with an increased risk of pancreatic and stomach cancer in both ...
Click to read the study in JAMA Oncology.
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to ...
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared ...
1. Women with a BRCA1 mutation had lower anti-Müllerian hormone (AMH) levels than non-carriers. 2. There was no association between ...
![Reduced neuronal BRCA1 associated with decreased DNA repair in Alzheimer’s disease [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/12/DNA_Furchen_edited-350x250.png)
1. In a pre-clinical study of post-mortem brains of Alzheimer’s disease (AD) patients, there was an isolated depletion of neuronal ...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Pembrolizumab ...
1. Oophorectomy was associated with decreased mortality in women with breast cancer and a BRCA1 mutation. 2. The survival benefit ...
